Peter Bruenker

532 total citations
9 papers, 61 citations indexed

About

Peter Bruenker is a scholar working on Radiology, Nuclear Medicine and Imaging, Oncology and Molecular Biology. According to data from OpenAlex, Peter Bruenker has authored 9 papers receiving a total of 61 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Radiology, Nuclear Medicine and Imaging, 6 papers in Oncology and 4 papers in Molecular Biology. Recurrent topics in Peter Bruenker's work include Radiopharmaceutical Chemistry and Applications (5 papers), Monoclonal and Polyclonal Antibodies Research (4 papers) and CAR-T cell therapy research (3 papers). Peter Bruenker is often cited by papers focused on Radiopharmaceutical Chemistry and Applications (5 papers), Monoclonal and Polyclonal Antibodies Research (4 papers) and CAR-T cell therapy research (3 papers). Peter Bruenker collaborates with scholars based in Switzerland, Germany and Netherlands. Peter Bruenker's co-authors include Thomas Friess, Martin J.S. Dyer, Adam Nopora, Samuel Moser, Christian Gerdes, Christian Klein, Sabine Bauer, Carla Schmidt, Tobias Suter and Ekkehard Moessner and has published in prestigious journals such as Blood, Cancer Research and European Journal of Cancer.

In The Last Decade

Peter Bruenker

7 papers receiving 61 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Peter Bruenker Switzerland	3	41	29	27	22	20	9	61
Yunhang Guo China	4	18 0.4×	31 1.1×	11 0.4×	39 1.8×	7 0.3×	4	66
Susie Brain United States	4	10 0.2×	34 1.2×	23 0.9×	22 1.0×	11 0.6×	12	57
Gunter Muth Switzerland	2	14 0.3×	28 1.0×	13 0.5×	25 1.1×	18 0.9×	2	40
Renunda Hicks United Kingdom	2	18 0.4×	8 0.3×	11 0.4×	11 0.5×	37 1.9×	2	68
Nathalie Steinhoff Switzerland	3	45 1.1×	13 0.4×	76 2.8×	4 0.2×	41 2.0×	5	94
Esther Bommer Switzerland	5	40 1.0×	9 0.3×	57 2.1×	3 0.1×	30 1.5×	5	66
Erica Hong United States	3	30 0.7×	9 0.3×	38 1.4×	4 0.2×	7 0.3×	5	53
Nurgul Kilavuz United States	4	13 0.3×	30 1.0×	49 1.8×	7 0.3×	18 0.9×	7	59
Hanlon Sia Australia	5	17 0.4×	12 0.4×	32 1.2×	14 0.6×	4 0.2×	22	55
P. Hoskins Canada	4	23 0.6×	20 0.7×	35 1.3×	2 0.1×	36 1.8×	4	83

Countries citing papers authored by Peter Bruenker

Since Specialization

Citations

This map shows the geographic impact of Peter Bruenker's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Bruenker with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Bruenker more than expected).

Fields of papers citing papers by Peter Bruenker

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Bruenker. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Bruenker. The network helps show where Peter Bruenker may publish in the future.

Co-authorship network of co-authors of Peter Bruenker

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Bruenker. A scholar is included among the top collaborators of Peter Bruenker based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Bruenker. Peter Bruenker is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

Gottschlich, Adrian, Johannes Sam, Lisa Rohrbacher, et al.. (2024). CSF1R Targeting T Cell Engaging Bispecific Antibodies Enable Safe and Efficient Immunotherapies in Acute Myeloid Leukemia. Blood. 144(Supplement 1). 918–918.

Stock, Sophia, Adrian Gottschlich, Lisa Rohrbacher, et al.. (2023). Adaptor Anti-P329G CAR T Cells for Modular Targeting of AML. Blood. 142(Supplement 1). 4805–4805.

Weber, Felix, Claas A. Meyer, Jens Niewoehner, et al.. (2018). First Infusion Reactions are Mediated by FcγRIIIb and Neutrophils. Pharmaceutical Research. 35(9). 169–169. 10 indexed citations

Bacac, Marina, Tanja Fauti, Sara Colombetti, et al.. (2015). Abstract 2481: CEA TCB, a novel T-cell bispecific antibody with potent in vitro and in vivo antitumor activity against solid tumors. Cancer Research. 75(15_Supplement). 2481–2481. 1 indexed citations

Friess, Thomas, et al.. (2015). Abstract C125: Preclinical pharmacodynamic biomarker and combination strategy of RG7386, a novel FAP-DR5 bispecific antibody for targeting solid tumors. Molecular Cancer Therapeutics. 14(12_Supplement_2). C125–C125. 1 indexed citations

Bacac, Marina, Tanja Fauti, Sara Colombetti, et al.. (2015). ITOC2 – 037. CEA TCB, A novel T-cell bispecific antibody with potent in vitro and in vivo antitumour activity against solid tumours. European Journal of Cancer. 51. S13–S13. 1 indexed citations

Wartha, Katharina, Barbara Weiser, Thomas Friess, et al.. (2014). Abstract 4573: A novel bispecific Fap-Dr5 antibody inducing potent and tumor-specific death receptor 5 (Dr5) activation by fibroblast activation protein (Fap)-dependent crosslinking. Cancer Research. 74(19_Supplement). 4573–4573. 1 indexed citations

Gerdes, Christian, Monika Patre, Valeria Nicolini, et al.. (2008). GA201, a novel humanized, glycoengineered EGFR antibody with enhanced ADCC and superior in vivo efficacy in xenograft models. Cancer Research. 68. 3973–3973. 3 indexed citations

Umaña, Pablo, Ekkehard Moessner, Peter Bruenker, et al.. (2006). Novel 3rd Generation Humanized Type II CD20 Antibody with Glycoengineered Fc and Modified Elbow Hinge for Enhanced ADCC and Superior Apoptosis Induction.. Blood. 108(11). 229–229. 44 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact